Diabetes, also known as hyperglycaemia, is caused when the glucose levels in the blood are higher than normal. With about 70 Million people suffering from the disease, India accounts for the world’s largest population of diabetic patients, and this number is expected to double within next twenty years.Obesity is the major cause of diabetes in India which is primarily the result ofchanging lifestyle patterns and sudden rise in middle-class population.After 1990s, there has been an immense increase in the disposable incomes led by economic growth in the country.
Owing to this, a large section of the population has adopted western dietary patterns including food rich in fat, sugar and calories. This, coupled with other factors such as growing sedentary lifestyle andlack of physical activityhave also contributed to the rising cases of diabetes in India. The latest report by IMARC Group titled, “Indian Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics”, finds that the Indian diabetes market reached a value of more than US$ 400 Million in 2016, growing at a CAGR of nearly 19% during 2009-2016. Further, the market is expected to reach a value of around US$ 3,600 Million by 2022, growing at a CAGR of around 17% during 2017-2022.
Request a free sample copy of the report: http://www.imarcgroup.com/request?type=report&id=550&flag=B
Highlights of Indian diabetes market:
- India accounts for the largest population of diabetic patients.
- Obesity represents the major cause for diabetes.
- Improvement in the healthcare infrastructurehave facilitated the growth of the market.
Mostly, healthy diet and proper exercise can help keeping blood sugar levels in check but in certain cases medication such as oral anti-diabetics and insulin therapy also need to be administered. Currently, oral anti-diabetics account for most of the diabetes market in India. Owing to increasing involvement of the government and non-government organisations people are being introduced to the importance of healthy lifestyle and management of non-communicable diseases. Moreover, an improvement in the healthcare infrastructure enabling the accessibility of diagnostics and drugs to both the urban and the rural population have also facilitated the growth of the market in the region.
Click here for summary of the report with TOC: http://www.imarcgroup.com/india-diabetes
The report provides the details of the major players operative in the market which include Abbot, Sanofi, Eli Lilly, USV, Sun Pharma, etc. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Indian diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Indian diabetes market in some form or the other.
Browse more related reports on Healthcare Industry: http://www.imarcgroup.com/categories/healthcare-market-research-reports
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.